ECOR
$6.25-0.30 (-4.65%)
electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally.
Recent News
electroCore, Inc. Q4 2025 Earnings Call Summary
Moby summary of electroCore, Inc.'s Q4 2025 earnings call
electroCore (ECOR) Q4 2025 Earnings Transcript
Joining me today are Dr. Thomas Errico, one of our founders and investor and Chairman of the electroCore Board of Directors; and Joshua Lev, our Chief Financial Officer. Before we begin, I want to express the privilege it is to address so many colleagues, partners, investors and their friends who have supported electroCore since I took the CEO position in late 2019.
electroCore Q4 Earnings Call Highlights
electroCore (NASDAQ:ECOR) executives highlighted record fourth-quarter revenue growth, expanding adoption within the U.S. Department of Veterans Affairs (VA) system, and accelerating sales of its Truvaga wellness product during the company’s fourth-quarter and full-year 2025 earnings call. Managemen
electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of +1.45% and -0.18%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
MARKER THERAPEUTICS (MRKR) delivered earnings and revenue surprises of +80.49% and +83.83%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?